{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:11:19Z","timestamp":1792710679731,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejves.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Vascular and Endovascular Surgery"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejvs.2024.07.017","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:19:31Z","timestamp":1720948771000},"page":"784-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry"],"prefix":"10.1016","volume":"68","author":[{"given":"E. Sebastian","family":"Debus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-4207","authenticated-orcid":false,"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-9142","authenticated-orcid":false,"given":"Robert C.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-7168","authenticated-orcid":false,"given":"Ala","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejvs.2024.07.017_bib1","first-page":"555","article-title":"Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study","volume":"30","author":"Blinc","year":"2011","journal-title":"Int Angiol"},{"key":"10.1016\/j.ejvs.2024.07.017_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ehj.2011.08.022","article-title":"Associations of symptomatic or asymptomatic peripheral arterial disease with all-cause mortality and cardiovascular mortality","volume":"63","author":"Daoud","year":"2011","journal-title":"Egyptian Heart J"},{"key":"10.1016\/j.ejvs.2024.07.017_bib3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","article-title":"Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2024.07.017_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejvs.2018.01.019","article-title":"Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome","volume":"55","author":"Sartipy","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2024.07.017_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ejvs.2024.07.017_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejvs.2021.10.037","article-title":"Geographical variation in the\u00a0management of peripheral arterial occlusive disease: a nationwide Danish cohort study","volume":"63","author":"S\u00f8gaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2024.07.017_bib7","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejvs.2024.07.017_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2024.07.017_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2024.07.017_bib10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejvs.2024.07.017_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejvs.2024.07.017_bib13","author":"Bayer"},{"key":"10.1016\/j.ejvs.2024.07.017_bib14","first-page":"1","article-title":"ESVM guideline on peripheral arterial disease","volume":"48","author":"Frank","year":"2019","journal-title":"Vasa"},{"key":"10.1016\/j.ejvs.2024.07.017_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2024.07.017_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2024.07.017_bib17","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2024.07.017_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2024.07.017_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ahj.2020.01.015","volume":"222","author":"Fox","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejvs.2024.07.017_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ehjcvp\/pvac028","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA Registry","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejvs.2024.07.017_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1358863X10373299","article-title":"Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry","volume":"15","author":"Suarez","year":"2010","journal-title":"Vasc Med"},{"key":"10.1016\/j.ejvs.2024.07.017_bib22","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejvs.2024.07.017_bib23","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ejvs.2024.07.017_bib24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cjca.2017.06.001","article-title":"Rationale, design and baseline characteristics of participants in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejvs.2024.07.017_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","article-title":"Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","volume":"199","author":"Capell","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejvs.2024.07.017_bib29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2018.07.046","article-title":"Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial","volume":"72","author":"Baumgartner","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ejvs.2024.07.017_bib30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2021.05.028","article-title":"External applicability of the COMPASS and VOYAGER-PAD trials on patients with symptomatic lower extremity artery disease in France: the COPART Registry","volume":"62","author":"Lapebie","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2024.07.017_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008069","article-title":"Impact of procedural bleeding in peripheral artery disease: an analysis from EUCLID trial","volume":"12","author":"Kansal","year":"2019","journal-title":"Circ Cardiovasc Interv"}],"container-title":["European Journal of Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107858842400621X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107858842400621X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T14:04:59Z","timestamp":1734012299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107858842400621X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S107858842400621X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejvs.2024.07.017","relation":{},"ISSN":["1078-5884"],"issn-type":[{"value":"1078-5884","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Vascular and Endovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejvs.2024.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Vascular Surgery.","name":"copyright","label":"Copyright"}]}}